Table 1.

Summary for each mutagen of the type of lesion incurred, the range of doses commonly used for sensitivity assays (Sections 2.3, 3.2, 3.3, 4.3, 5.2), the dose cited for immunofluorescence (αRAD-51, αRPA-1, αFCD-2) in the mitotic compartment, if available (Section 2.3, Step 15), and mutants strains with published sensitivity to the mutagen.

Mutagen	Lesion	Dose Range (Sensitivity)	Dose (Immunofluorescence)	Published Sensitive Strains
Cisplatin	ICL	90–360 μM	180 μM13,17	polq-1(tm2026)19 hel-308(tm2134)19 brc-1(tm1145)17 rfs-1(ok1372)17 fcd-2(tm1298)39
Nitrogen Mustard	ICL	50–200 μM	200 μM17	brc-1(tm1145)17 rfs-1(ok1372)17 rtel-1(tm1866)40 polq-1(tm2026)19 hel-308(tm2134)19 fcd-2(tm1298)13 dog-1(gk10)13 slx-1(tm2644)15
Psoralen	ICL	10 μg/ml + 50–200 J/m2 UVA	N/A	rtel-1(tm1866)40 fcd-2(tm1298)13 dog-1(gk10)13
Mitomycin C	ICL	250–500 μM	N/A	fan - 1(tm423)16 him-18(tm2181)16
Campothecin	RF stall	100–1000 nM	N/A	rtel-1(tm1866)40 him-18(tm2181)14 slx-1(tm2644)15 rfs-1(ok1372)17 brc-1(tm1145)17
γ-Irradiation	DSB	10–200 Gy	75 Gy	him-18(tm2181)14,15 brc-1(tm1145)17 rfs-1(ok1372)17 polq-1(tm2026)19 hel-308(tm2134)19
Hydroxyurea	RF stall	5–40 mM	40 mM17	clk-2(mn159)22